The global eosinophilic esophagitis market is anticipated to increase over the forecast period due to promising outcomes for potential treatment candidates. As a result, regulatory agencies including the U.S. Food and Drug Administration (FDA) are designating these medication candidates. Over the forecast period, this is anticipated to boost market growth. Over the projected period, it is anticipated that rising awareness campaigns for Eosinophil-associated illnesses will fuel the growth of the worldwide eosinophilic esophagitis market. The market is expected to increase over the forecast period as a result of several awareness programmes that have been created and put into place to inform the general public and the medical community about eosinophil-associated illnesses. The nonprofit American Partnership for Eosinophilic Diseases (APFED), which was established in December 2001, seeks to support and advocate for patients and families who are affected by eosinophil-associated disorders.
According to Coherent Market Insights, the global market for Eosinophilic Esophagitis is anticipated to reach US$138.4 million in 2021 and show a CAGR of 33.3% over the course of the projected period (2021-2028).
Market Leaders in the Eosinophilic Esophagitis Industry:
1. GlaxoSmithKline plc
The company was founded in 2000 and has its headquarters in London, England. GSK produces medications for common diseases such as diabetes, cancer, parasites, and psychological health. Three unsolicited bids to buy the Consumer Healthcare business unit from Unilever were received by the company, the company stated in January 2022. GSK released encouraging Phase IIa research results for a novel, first-in-class potential drug for tuberculosis patients in November 2022.
2. Teva Pharmaceutical Industries Ltd.
Israel's Tel Aviv serves as the company's headquarters, which was formed in 1901. Generic medications are its main area of expertise, but it also has certain additional business interests in active pharmaceutical ingredients and, to a lesser extent, patented pharmaceuticals. In January 19, 2023, the Science Based Targets programme (SBTi) will have externally validated Teva's ambitious climate targets. Following receiving widespread support from the states, Teva announced on January 9th, 2023 that the nationwide opioids settlement will proceed.
3. Takeda Pharmaceutical Company Limited
The pharmaceutical company Takeda was founded in 1781 and became a corporation on January 29, 1925. Oncology, uncommon illnesses, neurology, gastroenterology, particle medicine, and immunizations are the company's primary areas of interest. In February 2023, Nimbus Therapeutics' TYK2 Program Subsidiary was fully acquired by Takeda. To develop a first-in-class treatment for celiac disease, Takeda entered a collaboration and licencing agreement with Zedira and Dr. Falk Pharma in October 2022.
4. Cipla Limited
Cipla was founded in 1935 and Mumbai serves as the corporate headquarters for Cipla. Cipla primarily creates drugs to treat respiratory illnesses, cardiovascular illnesses, arthritis, diabetes, anxiety, and a variety of other illnesses. The business declared in July 2020 that Remdesivir from Gilead Sciences would be sold in India under the trade name CIPREMI.
5. Sun Pharmaceutical Industries Limited
Mumbai is home to Sun Pharmaceuticals, which was established in 1983. The company creates and markets active medicinal components and pharmaceutical formulations. Palbociclib, a breakthrough targeted medication for advanced breast cancer, is introduced by Sun Pharma in January 2023 with a special Patient Support Program. In March 2022, Sun Pharma launched its version of vortioxetine in India via an exclusive patent licence from Lundbeck.
6. AstraZeneca Plc
The business was founded in 1999 and has its corporate headquarters in Cambridge, UK. Its product line includes treatments for serious illnesses in the oncology, cardiac, digestive, infectious, neurological, respiratory, and inflammatory fields. It was announced in October 2022 that the business would purchase LogicBio Therapeutics, a player in clinical-stage genomic medicine. AstraZeneca announced in January 2023 that it would buy CinCor Pharma for $1.8 billion.
7. Sanofi S.A.
The company was created in 1973 and has its headquarters in Paris, France. Sanofi develops over-the-counter drugs in addition to doing research, developing pharmacological goods, manufacturing them, and selling them, mostly to the prescription market. It was revealed on November 18, 2021, that Sanofi would contribute $180 million to the French firm Owkin.
8. Glenmark Pharmaceuticals
It was established in 1977 and Mumbai serves as the corporate headquarters. The business produces a generic medicine and an active pharmaceutical component. Favipiravir, a prospective COVID-19 medication, was introduced by the business in India in June 2020 under the trade name FabiFlu.
9. Alkem Laboratories Limited
It was established in 1973 and Mumbai serves as the corporate headquarters. The company produces and markets pharmaceutical formulations, generic drugs, and dietary supplements both domestically and internationally.
Definition: Esophagitis with eosinophilia is a persistent immune system condition. Eosinophils, a type of white blood cell, accumulate in the lining of the tube that connects your mouth to your stomach when you have this disease. The oesophagus is another name for this tube.
